Hormonal contraceptive choices in a clinic-based series of transgender adolescents and young adults
- 1 July 2019
- journal article
- research article
- Published by Taylor & Francis in International Journal of Transgenderism
- Vol. 20 (4) , 413-420
Abstract
Aims: To describe the use of hormonal contraceptives for menstrual management and/or pregnancy prevention in a clinic-based series of transgender adolescents and young adults who were assigned female at birth (transmasculine identity). Methods: We performed a chart review of post-menarchal transgender assigned-female-at-birth (AFAB) patients, age 10–25 years, seen at CCHMC Transgender Health Clinic for at least 2 visits between July 1, 2013 and September 17, 2016, and who were not on a puberty suppression method. We collected data including choice of hormonal contraceptive and indication (menstrual suppression, pregnancy prevention, or both), duration of use, initiation of sexual activity, reported sexual partners, and use of gender-affirming hormone therapy (i.e., testosterone). We present simple descriptive statistics. Results: A total of 231 patients met inclusion criteria, with ages from 11 to 25 years. Of those, 135 (59%) were using a hormonal contraceptive method. Most patients (67%) used hormonal contraception for the indication of menstrual suppression. Most commonly used method was depot medroxyprogesterone (DMPA) (49 patients), followed by combined oral contraceptives (COC) and norethindrone (progestin-only pill, POP) (34 patients each). Thirteen patients used 52 mg levonorgestrel IUD (LNG-IUD). Of the total sample (n = 231), 82 (36%) reported sexual activity, 35 of whom (43% of sexually active patients) reported sexual intercourse with assigned-male-at-birth (AMAB) partners and/or penile–vaginal intercourse. Among 35 patients at risk for pregnancy, only 21 (60%) were using hormonal contraception. Over half (54%) of sexually active patients taking testosterone discontinued their hormonal contraceptive method once they stopped having menses. Discussion: Within a sample of transgender AFAB adolescents, half of whom were taking testosterone, a variety of contraceptives were used, including depot medroxyprogesterone, combined oral contraceptives, and levonorgestrel IUD. Among those taking testosterone, many patients discontinued contraception once they stopped having menses.Keywords
Funding Information
- The Academic and Research Committee
This publication has 31 references indexed in Scilit:
- Association of Hormonal Contraceptive Use With Reduced Levels of Depressive Symptoms: A National Study of Sexually Active Women in the United StatesAmerican Journal of Epidemiology, 2013
- Further evidence for lack of negative associations between hormonal contraception and mental healthContraception, 2012
- Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7International Journal of Transgenderism, 2012
- Depression in Trans People: A Review of the Risk FactorsInternational Journal of Transgenderism, 2012
- Children and Adolescents With Gender Identity Disorder Referred to a Pediatric Medical CenterPediatrics, 2012
- Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: A nationwide population-based study with age-specific analysesThe European Journal of Contraception & Reproductive Health Care, 2012
- Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based studyThe European Journal of Contraception & Reproductive Health Care, 2010
- Infertility in Polycystic Ovary Syndrome: Focus on Low-Dose Gonadotropin TreatmentEndocrine, 2006
- The pregnant man—an oxymoron?Journal of Gender Studies, 1998
- Histological changes in the genital tract in transsexual women following androgen therapyHistopathology, 1986